YS Biopharma Co., Ltd. (NASDAQ:YS - Get Free Report) shares rose 7.6% during trading on Friday . The stock traded as high as $0.85 and last traded at $0.84. Approximately 398,477 shares were traded during mid-day trading, an increase of 131% from the average daily volume of 172,401 shares. The stock had previously closed at $0.78.
YS Biopharma Price Performance
The company has a debt-to-equity ratio of 0.26, a current ratio of 0.94 and a quick ratio of 0.73. The firm's fifty day moving average is $0.52 and its two-hundred day moving average is $0.67.
Institutional Investors Weigh In On YS Biopharma
An institutional investor recently bought a new position in YS Biopharma stock. Superstring Capital Management LP bought a new position in YS Biopharma Co., Ltd. (NASDAQ:YS - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 307,920 shares of the company's stock, valued at approximately $166,000. Superstring Capital Management LP owned approximately 0.33% of YS Biopharma at the end of the most recent reporting period. Hedge funds and other institutional investors own 52.64% of the company's stock.
YS Biopharma Company Profile
(
Get Free Report)
YS Biopharma Co, Ltd., a biopharmaceutical company, engages in discovering, developing, manufacturing, and commercializing of vaccines and therapeutic biologics for infectious diseases and cancer. The company develops a proprietary PIKA immunomodulating technology platform and a series of product targeting PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, and PIKA YS-ON-001.
Further Reading
Before you consider YS Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and YS Biopharma wasn't on the list.
While YS Biopharma currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
